BetterLife Announces Debt Settlements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Source: Newsfilter
Company Financial Update: BetterLife Pharma Inc. has issued 14,999,303 common shares to settle accounts payable totaling $1,499,930, including 10,308,039 shares for $1.03 million owed to directors and officers, and an additional 250,000 shares from the exercise of share purchase warrants for $25,000.
Product Development Focus: The company is developing BETR-001, a non-hallucinogenic neuroplastogen for psychiatric disorders, and BETR-002, aimed at treating anxiety-related disorders, while also exploring strategic alternatives for a drug candidate targeting viral infections.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
